Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 7:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 108 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Asthma in Children
Interventions
Inhaled corticosteroid (mometasone)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 20 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Chronic Sinusitis
Interventions
Propel Nova Sinus Implant
Device
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Miami, Florida • Dublin, Ohio
Conditions
Asthma
Interventions
Placebo, Mometasone Furoate
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Omaha, Nebraska
Completed No phase listed Interventional Accepts healthy volunteers Results available

A Clinical Evaluation of the Intersect ENT Sinus Device (ASCEND)

NCT03599271
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Drug-Coated Device, Control Device
Device
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Nasal Polyps, Chronic Rhinosinusitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Tucson, Arizona • Rancho Cordova, California + 13 more
Conditions
Asthma
Interventions
Formoterol fumarate 10 mcg, Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
12 Years to 120 Years
Enrollment
10,288 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency, ATP-Binding Cassette Subfamily C Member 6 Deficiency
Interventions
No Intervention for this observational study
Other
Lead sponsor
Inozyme Pharma
Industry
Eligibility
Not listed
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 2 more
Completed Phase 3 Interventional Results available

Steroids In Eosinophil Negative Asthma

NCT02066298
Conditions
Asthma
Interventions
Mometasone 220mcg BID, Tiotropium Respimat 5mcg QD, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
25
States / cities
Tucson, Arizona • San Francisco, California • Denver, Colorado + 13 more
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Adjunctive Treatment for Chronic Rhinosinusitis With Nasal Polyposis

NCT03607175
Conditions
Chronic Rhinosinusitis, Nasal Polyps
Interventions
Triamcinolone-impregnated CMC foam, Propel Stent
Drug · Device
Lead sponsor
Marina Boruk
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Hypersensitivity
Interventions
Mometasone furoate drug formulation (MFF) 1, Mometasone furoate drug formulation (MFF) 2
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Sickle Cell Disease
Interventions
Placebo, Mometasone
Drug
Lead sponsor
Jeffrey Glassberg
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
New York, New York
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis

NCT03705793
Conditions
Chronic Rhinosinusitis (Diagnosis), Allergic Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis
Interventions
Mometasone Furoate Nasal Irrigation, Mometasone Nasal Spray
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
St Louis, Missouri
Conditions
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Interventions
Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate 50 micrograms
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
18
States / cities
Long Beach, California • Orange, California • San Diego, California + 15 more
Completed Phase 4 Interventional Results available

Study of Asthma and Nasal Steroids

NCT01118312
Conditions
Asthma, Rhinitis, Sinusitis
Interventions
Mometasone Furoate monohydrate, Placebo
Drug · Other
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
6 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
19
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 16 more
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Lunsekimig, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
9
States / cities
La Jolla, California • Roseville, California • Boise, Idaho + 6 more
Completed Not applicable Interventional Accepts healthy volunteers

MapTrek to Increase Activity Among Patients at Risk for Type 2 Diabetes

NCT03193229
Conditions
Pre Diabetes, Obesity
Interventions
MapTrek, Fitbit
Behavioral · Device
Lead sponsor
Philip Polgreen
Other
Eligibility
21 Years to 80 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Coralville, Iowa
Conditions
Seasonal Allergic Rhinitis
Interventions
GSP 301-1 NS (QD), GSP 301-2 NS (BID), GSP 301 Placebo NS, Olopatadine HCl-1 NS (QD), Olopatadine HCl-2 NS (BID), Mometasone Furoate-1 NS (QD), Mometasone Furoate-2 NS (BID)
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years and older
Enrollment
1,111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Conditions
Seasonal Allergic Rhinitis
Interventions
Mometasone furoate, Nasonex Nasal Spray, Placebo nasal spray
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • La Mesa, California • Los Angeles, California + 12 more
Conditions
Asthma
Interventions
Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF
Drug
Lead sponsor
Novartis
Industry
Eligibility
5 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Mobile, Alabama • Huntington Beach, California • Orange, California + 3 more
Conditions
Chronic Sinusitis
Interventions
Sinus Stent with drug coating, Non Coated Sinus Stent
Device
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Fresno, California • Colorado Springs, Colorado • Chicago, Illinois + 8 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of Pushrim Activated Power Assist Wheelchairs on Mobility Among People With Tetraplegia

NCT00281463
Conditions
Wheelchair Users
Interventions
Pushrim Activated Power Assist
Device
Lead sponsor
VA Pittsburgh Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Asthma
Interventions
Mometasone, Advair
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Invasive Breast Cancer
Interventions
Eucerin, Mometasone Furoate 0.1%
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more